Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

Andrea Marzi; Aisling A. Murphy; F Feldmann; Christopher J. Parkins; Elaine Haddock; Patrick W. Hanley; Matthew J. Emery; Flora Engelmann; Ilhem Messaoudi; H Feldmann; Michael A. Jarvis

doi:10.1038/srep21674

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

Andrea Marzi, Aisling A. Murphy, F Feldmann, Christopher J. Parkins, Elaine Haddock, Patrick W. Hanley, Matthew J. Emery, Flora Engelmann, Ilhem Messaoudi, H Feldmann, Michael A. Jarvis^*

^*Corresponding author for this work

School of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

6 Downloads (Pure)

Abstract

AbstractEbolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.

Original language	English
Number of pages	0
Journal	Scientific Reports
Volume	6
Issue number	1
DOIs	https://doi.org/10.1038/srep21674
Publication status	E-pub ahead of print - 15 Feb 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep21674

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

Cite this

Marzi, A., Murphy, A. A., Feldmann, F., Parkins, C. J., Haddock, E., Hanley, P. W., Emery, M. J., Engelmann, F., Messaoudi, I., Feldmann, H., & Jarvis, M. A. (2016). Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Scientific Reports, 6(1). Advance online publication. https://doi.org/10.1038/srep21674

@article{0033bf7dff8e4e5bb107d2ca678d229f,

title = "Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection",

abstract = "AbstractEbolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.",

author = "Andrea Marzi and Murphy, {Aisling A.} and F Feldmann and Parkins, {Christopher J.} and Elaine Haddock and Hanley, {Patrick W.} and Emery, {Matthew J.} and Flora Engelmann and Ilhem Messaoudi and H Feldmann and Jarvis, {Michael A.}",

year = "2016",

month = feb,

day = "15",

doi = "10.1038/srep21674",

language = "English",

volume = "6",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

AU - Marzi, Andrea

AU - Murphy, Aisling A.

AU - Feldmann, F

AU - Parkins, Christopher J.

AU - Haddock, Elaine

AU - Hanley, Patrick W.

AU - Emery, Matthew J.

AU - Engelmann, Flora

AU - Messaoudi, Ilhem

AU - Feldmann, H

AU - Jarvis, Michael A.

PY - 2016/2/15

Y1 - 2016/2/15

N2 - AbstractEbolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.

AB - AbstractEbolaviruses pose significant public health problems due to their high lethality, unpredictable emergence, and localization to the poorest areas of the world. In addition to implementation of standard public health control procedures, a number of experimental human vaccines are being explored as a further means for outbreak control. Recombinant cytomegalovirus (CMV)-based vectors are a novel vaccine platform that have been shown to induce substantial levels of durable, but primarily T-cell-biased responses against the encoded heterologous target antigen. Herein, we demonstrate the ability of rhesus CMV (RhCMV) expressing Ebola virus (EBOV) glycoprotein (GP) to provide protective immunity to rhesus macaques against lethal EBOV challenge. Surprisingly, vaccination was associated with high levels of GP-specific antibodies, but with no detectable GP-directed cellular immunity.

U2 - 10.1038/srep21674

DO - 10.1038/srep21674

M3 - Article

SN - 2045-2322

VL - 6

JO - Scientific Reports

JF - Scientific Reports

IS - 1

ER -

Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this